The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2022 | Next steps for the development of individualised mRNA neoantigen vaccines
Vinod Balachandran, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses challenges for implementing individualised mRNA neoantigen vaccines in clinical practice, including the need for a universal strategy for selecting neoantigen targets, as well as further investigation as to the scientific rationale and clinical efficacy of the vaccines. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
